MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Lian Xu, Zachary R. Hunter, Guang Yang, Yangsheng Zhou, Yang Cao, Xia Liu, Enrica Morra, Alessandra Trojani, Antonino Greco, Luca Arcaini, Maria Varettoni, Jennifer R. Brown, Yu Tzu Tai, Kenneth C. Anderson, Nikhil C. Munshi, Christopher J. Patterson, Robert J. Manning, Christina K. Tripsas, Neal I. Lindeman, Steven P. Treon

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P <1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.

Original languageEnglish
Pages (from-to)2051-2058
Number of pages8
JournalBlood
Volume121
Issue number11
DOIs
Publication statusPublished - Mar 14 2013

Fingerprint

Waldenstrom Macroglobulinemia
Paraproteinemias
Lymphoproliferative Disorders
Polymerase chain reaction
Monoclonal Gammopathy of Undetermined Significance
Immunoglobulin M
B-Lymphocytes
Alleles
Cells
Polymerase Chain Reaction
Assays
Patient treatment
Mutation
Immunoglobulin G
Genes
Multiple Myeloma
Lymphoma
Tissue Donors
Genome

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. / Xu, Lian; Hunter, Zachary R.; Yang, Guang; Zhou, Yangsheng; Cao, Yang; Liu, Xia; Morra, Enrica; Trojani, Alessandra; Greco, Antonino; Arcaini, Luca; Varettoni, Maria; Brown, Jennifer R.; Tai, Yu Tzu; Anderson, Kenneth C.; Munshi, Nikhil C.; Patterson, Christopher J.; Manning, Robert J.; Tripsas, Christina K.; Lindeman, Neal I.; Treon, Steven P.

In: Blood, Vol. 121, No. 11, 14.03.2013, p. 2051-2058.

Research output: Contribution to journalArticle

Xu, L, Hunter, ZR, Yang, G, Zhou, Y, Cao, Y, Liu, X, Morra, E, Trojani, A, Greco, A, Arcaini, L, Varettoni, M, Brown, JR, Tai, YT, Anderson, KC, Munshi, NC, Patterson, CJ, Manning, RJ, Tripsas, CK, Lindeman, NI & Treon, SP 2013, 'MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.', Blood, vol. 121, no. 11, pp. 2051-2058. https://doi.org/10.1182/blood-2012-09-454355
Xu, Lian ; Hunter, Zachary R. ; Yang, Guang ; Zhou, Yangsheng ; Cao, Yang ; Liu, Xia ; Morra, Enrica ; Trojani, Alessandra ; Greco, Antonino ; Arcaini, Luca ; Varettoni, Maria ; Brown, Jennifer R. ; Tai, Yu Tzu ; Anderson, Kenneth C. ; Munshi, Nikhil C. ; Patterson, Christopher J. ; Manning, Robert J. ; Tripsas, Christina K. ; Lindeman, Neal I. ; Treon, Steven P. / MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. In: Blood. 2013 ; Vol. 121, No. 11. pp. 2051-2058.
@article{7278972a81f044998de559f37a82b6b1,
title = "MYD88 L265P in Waldenstr{\"o}m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.",
abstract = "By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90{\%} of Waldenstr{\"o}m macroglobulinemia (WM) patients. MYD88 L265P was absent in 90{\%} of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93{\%}) WM and 13 of 24 (54{\%}) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10{\%}), CLL (1/26; 4{\%}), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P <1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.",
author = "Lian Xu and Hunter, {Zachary R.} and Guang Yang and Yangsheng Zhou and Yang Cao and Xia Liu and Enrica Morra and Alessandra Trojani and Antonino Greco and Luca Arcaini and Maria Varettoni and Brown, {Jennifer R.} and Tai, {Yu Tzu} and Anderson, {Kenneth C.} and Munshi, {Nikhil C.} and Patterson, {Christopher J.} and Manning, {Robert J.} and Tripsas, {Christina K.} and Lindeman, {Neal I.} and Treon, {Steven P.}",
year = "2013",
month = "3",
day = "14",
doi = "10.1182/blood-2012-09-454355",
language = "English",
volume = "121",
pages = "2051--2058",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

AU - Xu, Lian

AU - Hunter, Zachary R.

AU - Yang, Guang

AU - Zhou, Yangsheng

AU - Cao, Yang

AU - Liu, Xia

AU - Morra, Enrica

AU - Trojani, Alessandra

AU - Greco, Antonino

AU - Arcaini, Luca

AU - Varettoni, Maria

AU - Brown, Jennifer R.

AU - Tai, Yu Tzu

AU - Anderson, Kenneth C.

AU - Munshi, Nikhil C.

AU - Patterson, Christopher J.

AU - Manning, Robert J.

AU - Tripsas, Christina K.

AU - Lindeman, Neal I.

AU - Treon, Steven P.

PY - 2013/3/14

Y1 - 2013/3/14

N2 - By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P <1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.

AB - By whole-genome and/or Sanger sequencing, we recently identified a somatic mutation (MYD88 L265P) that stimulates nuclear factor κB activity and is present in >90% of Waldenström macroglobulinemia (WM) patients. MYD88 L265P was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) patients. We therefore developed conventional and real-time allele-specific polymerase chain reaction (AS-PCR) assays for more sensitive detection and quantification of MYD88 L265P. Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P <1.5 × 10(-5) for WM vs other cohorts). Real-time AS-PCR identified IgM MGUS patients progressing to WM and showed a high rate of concordance between MYD88 L265P ΔCT and BM disease involvement (r = 0.89, P = .008) in WM patients undergoing treatment. These studies identify MYD88 L265P as a widely present mutation in WM and IgM MGUS patients using highly sensitive and specific AS-PCR assays with potential use in diagnostic discrimination and/or response assessment. The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84877343691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877343691&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-09-454355

DO - 10.1182/blood-2012-09-454355

M3 - Article

VL - 121

SP - 2051

EP - 2058

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -